Hongli Yu
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Consensus on standardized later-line systemic therapy for hepatocellular carcinoma.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: May 11, 2026
A Single‑Center Retrospective Cohort Study: Impact of Glycemic Control on First‑Line TKI Plus PD‑1 Inhibitors versus TKI Alone in Intermediate‑to‑advanced Unresectable Hepatocellular Carcinoma(HCC) with Type 2 Diabetes Mellitus (T2DM).
Journal: Journal of hepatocellular carcinoma
Published: April 24, 2026
Kinesiophobia in patients with diabetic foot ulcers: A multicenter latent profile analysis of phenotypic characteristics and determinants.
Journal: Journal of tissue viability
Published: March 19, 2026
Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.
Journal: Medical review (2021)
Published: November 18, 2025
Predicting the Occurrence of Cachexia in Patients with BCLC Stage B/C Hepatocellular Carcinoma Receiving Systemic Therapy: A Nomogram Based on Common Clinical Parameters.
Journal: Journal of hepatocellular carcinoma
Published: August 21, 2025
A Multicenter Retrospective Study: Impact of First-Line Treatment Strategies on second-Line Efficacy and Safety of Regorafenib with or Without PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: May 07, 2025
Practice revolution in local interventional therapy for liver metastases.
Journal: iLIVER
Published: March 06, 2025
Showing 1-10 of 10
Last Updated: 09/26/2026